MANKIND PHARMA Q4 CONCALL HIGHLIGHTS
■ Consumer Healthcare (OTC):
FY25 Revenue: ₹890 Cr (+15%)
Modern trade & e-comm: +77%
EBITDA margin in high teens; ~7% of total sales
■ BSV Acquisition:
Strengthened presence in gynecology; IPM share now 4.8% (value), 6% (volume)
Integration costs: ₹25 Cr in Q4
Targeting 18–20% growth for BSV; >20% for international
Synergies of ₹50–100 Cr expected in 12–24 months
Join👇👇
@Stock_aaj_or_kal
■ Consumer Healthcare (OTC):
FY25 Revenue: ₹890 Cr (+15%)
Modern trade & e-comm: +77%
EBITDA margin in high teens; ~7% of total sales
■ BSV Acquisition:
Strengthened presence in gynecology; IPM share now 4.8% (value), 6% (volume)
Integration costs: ₹25 Cr in Q4
Targeting 18–20% growth for BSV; >20% for international
Synergies of ₹50–100 Cr expected in 12–24 months
Join👇👇
@Stock_aaj_or_kal
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
